USA - NASDAQ:MOTS - US62014P5044 - Common Stock
The current stock price of MOTS is 0.1735 USD. In the past month the price decreased by -72.53%. In the past year, price decreased by -98.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| RMD | RESMED INC | 24.94 | 36.03B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B | ||
| STE | STERIS PLC | 24.71 | 23.21B |
Motus GI Holdings Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fort Lauderdale, Florida and currently employs 43 full-time employees. The company went IPO on 2018-02-14. Motus GI Holdings, Inc. is a medical technology company. The Company, through its subsidiaries in the United States and Israel, is engaged in providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The company has developed the Pure-Vu System, a medical device that helps to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (GI) endoscopy procedures. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Its system consists of a workstation controller and a single-use, disposable sleeve that fits over standard and slim colonoscopes. The Company’s wholly owned subsidiaries include Motus GI Medical Technologies, Ltd. and Motus GI, LLC.
MOTUS GI HOLDINGS INC
1301 E Broward Blvd Fl 3
FORT LAUDERDALE FLORIDA 33301 US
CEO: Timothy P. Moran
Employees: 43
Phone: 17864591831
Motus GI Holdings Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fort Lauderdale, Florida and currently employs 43 full-time employees. The company went IPO on 2018-02-14. Motus GI Holdings, Inc. is a medical technology company. The Company, through its subsidiaries in the United States and Israel, is engaged in providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The company has developed the Pure-Vu System, a medical device that helps to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (GI) endoscopy procedures. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Its system consists of a workstation controller and a single-use, disposable sleeve that fits over standard and slim colonoscopes. The Company’s wholly owned subsidiaries include Motus GI Medical Technologies, Ltd. and Motus GI, LLC.
The current stock price of MOTS is 0.1735 USD. The price decreased by -34.06% in the last trading session.
MOTS does not pay a dividend.
MOTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
MOTUS GI HOLDINGS INC (MOTS) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
MOTUS GI HOLDINGS INC (MOTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28.56).
The outstanding short interest for MOTUS GI HOLDINGS INC (MOTS) is 0.12% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to MOTS. Both the profitability and financial health of MOTS have multiple concerns.
Over the last trailing twelve months MOTS reported a non-GAAP Earnings per Share(EPS) of -28.56. The EPS increased by 68.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -178.25% | ||
| ROE | -479.16% | ||
| Debt/Equity | 0.46 |
7 analysts have analysed MOTS and the average price target is 8.47 USD. This implies a price increase of 4779.54% is expected in the next year compared to the current price of 0.1735.
For the next year, analysts expect an EPS growth of 58.34% and a revenue growth 337.5% for MOTS